

#13  
02/13/97/12

**STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.**

ATTORNEYS AT LAW

SUITE 600

1100 NEW YORK AVENUE, N.W.

WASHINGTON, D.C. 20005-3934

(202) 371-2600

FACSIMILE: (202) 371-2540

ROBERT GREENE STERNE  
EDWARD J. KESSLER  
JORGE A. GOLDSTEIN  
SAMUEL L. FOX  
DAVID K.S. CORNWELL  
ROBERT W. ESMOND  
TRACY-GENE G. DURKIN  
MICHELE A. CIMBALA  
MICHAEL B. RAY  
ROBERT E. SOKOHL  
WILLIAM C. ALLISON

MICHAEL O. LEE  
ERIC K. STEFFE  
ANDREA G. REISTER  
DANIEL N. YANNUZZI  
G. KEVIN TOWNSEND\*  
JOHN M. COVERT\*  
ANNE BROWN  
MICHELE A. VAN PATTEN\*  
LINDA E. ALCORN  
RAZ E. FLESHNER  
ROBERT C. MILLONIG

STEVEN R. LUDWIG  
MICHAEL V. MESSINGER  
LORI L. KERBER\*  
JUDITH U. KIM\*  
KEITH KIND\*  
TIMOTHY J. SHEA, JR.\*  
DONALD R. MCPHAIL  
PATRICK E. GARRETT\*  
NAREN R. THAPPETA\*  
JEFFREY W. RENNECKER

DONALD J. FEATHERSTONE\*\*  
LAWRENCE B. BUGAISKY\*\*  
KAREN R. MARKOWICZ\*\*  
KIMBERLIN M. TOOHEY\*\*

\*BAR OTHER THAN D.C.  
\*\*REGISTERED PATENT AGENTS

WRITER'S DIRECT NUMBER:  
(202) 371-2637

INTERNET ADDRESS:

KAREN@SKGF.com



January 23, 1997

RECEIVED

JAN 29 1997

GROUP 1800

Assistant Commissioner for Patents  
Washington, D.C. 20231

Re: U.S. Utility Patent Application  
Appl. No. 08/469,637; Filed: June 6, 1995  
For: **Human Tumor Necrosis Factor Receptor**  
Inventors: GREENE *et al.*  
Our Ref: 1488.0710001/EKS/KRM

Sir:

Transmitted herewith for appropriate action are the following documents:

1. Information Disclosure Statement;
2. PTO Form-1449 (6 pages) with 22 references; and
3. One (1) Return Postcard.

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier.

Assistant Commissioner for Patents


January 23, 1997

Page 2

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036. A duplicate copy of this letter is enclosed.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Karen R. Markowicz  
Agent for Applicants  
Registration No. 36,351

EKS:KRM:cd

Attachments

a:\071-1.tr3

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

GREENE *et al.*

Appl. No. 08/469,637


Filed: June 6, 1995

Art Unit: 1812

Examiner: Pak, M.

Atty. Docket: 1488.0710001

For: **Human Tumor Necrosis Factor  
Receptor**



**Information Disclosure Statement**

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

Listed on accompanying Form PTO-1449 are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98. Copies of these documents are provided.

The Examiner is also referred to the following list of co-pending patent applications:

Appl. No. 60/013,285, filed March 12, 1996;  
Appl. No. 60/028,711, filed October 17, 1996;  
Appl. No. 08/462,315, filed June 5, 1995;  
Appl. No. 08/462,962, filed June 5, 1995;  
Appl. No. 08/464,595, filed June 5, 1995;  
Appl. No. 08/741,095, filed October 30, 1996; and  
Appl. No. 08/718,737, filed September 18, 1996.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached PTO-1449 based on information presently available to

the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.


This statement should not be construed as a representation that an exhaustive search has been made, or that there does not exist information more material to the examination of the present patent application. The Examiner is specifically requested not to rely solely on the material submitted herewith. It is understood that the Examiner will review art of record in all 35 U.S.C. § 120 priority documents.

It is respectfully requested that the Examiner initial and return a copy of the enclosed PTO-1449 and indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Karen R. Markowicz  
Agent for Applicants  
Registration No. 36,351

Date: 1/23/97

1100 New York Avenue, N.W.  
Suite 600  
Washington, D.C. 20005  
(202) 371-2600  
KRM/ajk